Indicators

Antithrombotic therapy

QUM domain: Safe and effective use

1.5 Percentage of patients with an INR above 4 whose dosage has been adjusted or reviewed prior to the next warfarin dose

Purpose

This indicator addresses the effectiveness of processes for timely and effective monitoring of high risk medicines such as warfarin.

Background and evidence

Warfarin has a narrow therapeutic index, thus monitoring therapy is critical to prevent harm. The anticoagulant effect of warfarin is monitored by calculating the International Normalised Ratio (INR) – a ratio of the patient’s prothrombin time to the mean normal prothrombin time.1 For most patients requiring warfarin, the target INR range is between 2 and 3.1,2

Bleeding is the most common and serious complication of warfarin2 and there is a strong relationship between INR levels and bleeding.3 The risk of bleeding is markedly increased once the INR exceeds 4.4

To reduce bleeding risk, dosage adjustment is often needed, particularly for those patients newly initiated on warfarin and/or other medication. This includes patients on warfarin who are hospitalised for conditions unrelated to the requirement for warfarin. However, watchful waiting is an acceptable alternative in patients with mildly elevated INR.5 Therefore in some cases it may be appropriate that no dosage adjustment occurs, although regular review is mandatory.

Key definitions

Dosage adjusted is defined as dose reduction or dose omission and must be documented on the medication chart.

Dosage reviewed means there is explicit documentation on the medication chart or in another pre-determined section of the medical record that a high INR has been noted and that dosage adjustment is not required.

Data collection for local use

Please refer to the section Using the National Quality Use of Medicines Indicators for Australian Hospitals for guidance on sample selection, sample size, measurement frequency and other considerations.

Inclusion criteria: Patients aged 18 years and over with an INR result greater than 4.

Exclusion criteria: Nil.

Recommended data sources: Medical records, medication charts and pathology results.

The data collection tool for QUM Indicator 1.5 assists data collection and indicator calculation.

Data collection for inter-hospital comparison

This indicator may be suitable for inter-hospital comparison. In this case, definitions, sampling methods and guidelines for audit and reporting need to be agreed in advance in consultation with the coordinating agency.

Indicator calculation



Numerator = Number of patients with INR above 4 whose dosage has been adjusted or reviewed prior to the next warfarin dose

Denominator = Number of patients with INR above 4 in sample

Limitations and interpretation

Data collection for this indicator relies on documentation in the medical record, especially for demonstration of dosage review. Good documentation supports quality patient care6 and is a critical component of management for potentially toxic medicines such as warfarin. Poor communication can result in adverse drug events.7 Thus it is assumed that absence of explicit documentation means no review took place.

|  |
| --- |
| Further informationMedication Safety Self Assessment for Antithrombotic Therapy in Australian Hospitals8 (MSSA-AT) can help identify potential strategies for improvement with this and other indicators. The MSSA-AT encourages development of robust systems for safe prescribing, dispensing, administration and monitoring of antithrombotic therapy. MSSA-AT is available at [www.cec.health.nsw.gov.au](http://www.cec.health.nsw.gov.au)This indicator can be used to assist hospitals in meeting the National Safety and Quality Health Service Standard 1 [items 1.2.1, 1.2.2, 1.5.2, 1.6.1, 1.6.2, 1.8.1] and Standard 4 [items 4.2.1, 4.2.2, 4.5.1, 4.5.2, 4.11.1].9 |

References

1. Hirsh J, Dalen J, Anderson D, et al. Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest 2001; 119: 8-21.

2. Australian Medicines Handbook. Australian Medicines Handbook Pty Ltd, 2012

3. Levine M, Raskob G, Beyth R, et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: S287-S310.

4. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497.

5. Banet GA, Waterman AD, Milligan PE, et al. Warfarin dose reduction vs watchful waiting for mild elevations in the International Normalized Ratio. Chest 2003; 123: 499-503.

6. The Good Clinical Documentation Guide. National Centre for Classification in Health, Commonwealth of Australia, 2003.

7. MacKinnon NJ, ed. Safe and Effective: The Eight Essential Elements of an Optimal Medication-use System. Canadian Pharmacists Association, 2007.

8. Medication Safety Self Assessment for Antithrombotic Therapy in Australian Hospitals: Institute for Safe Medication Practices USA (Adapted for Australian use by NSW Therapeutic Advisory Group and the Clinical Excellence Commission), 2007.

9. Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. Sydney, ACSQHC, 2012.

Australian Commission on Safety and Quality in Health Care

Level 5, 255 Elizabeth St, Sydney NSW 2001

GPO Box 5480, Sydney NSW 2001

Phone: (02) 9126 3600 (international +61 2 9126 3600)

Fax: (02) 9126 3613 (international +61 2 9126 3613)

Email: mail@safetyandquality.gov.au

[www.safetyandquality.gov.au](http://www.safetyandquality.gov.au)

NSW Therapeutic Advisory Group Inc

26 Leichhardt St, Darlinghurst NSW 2010

PO Box 766, Darlinghurst NSW 2010

Phone: (02) 8382 2852 (international +61 2 8382 2852)

Fax: (02) 8382 3529 (international +61 2 8382 3529)

Email: nswtag@stvincents.com.au

[www.nswtag.org.au](http://www.nswtag.org.au)